{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T08:30:55Z","timestamp":1765873855339,"version":"3.48.0"},"reference-count":42,"publisher":"BMJ","issue":"11","funder":[{"DOI":"10.13039\/501100000106","name":"Saskatchewan Health Research Foundation","doi-asserted-by":"crossref","award":["3821"],"award-info":[{"award-number":["3821"]}],"id":[{"id":"10.13039\/501100000106","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2019,11,7]]},"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Disease-modifying therapy (DMT) use in multiple sclerosis (MS) has increased significantly. However, the impact of DMTs on healthcare use is limited and conflicting, and rarely examined at a population level. This study examined the association between DMTs and healthcare utilisation at the population level.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Health administrative data from Saskatchewan, Canada (1997\u20132016).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>To test for associations at the population level, we identified two cohorts. The general population cohort included all Saskatchewan residents \u226518 years who were drug plan beneficiaries. The MS cohort included individuals \u226518 years, identified using a validated definition (\u22653 hospital, physician or drug claims for MS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures and methods<\/jats:title>\n                    <jats:p>To test for an association between the total number of DMT dispensations per year and the total number of hospitalisations we used negative binomial regression fitted with generalised estimating equations (GEE); only hospitalisations that occurred after the date of MS diagnosis (date of first claim for MS or demyelinating disease) were extracted. To test for an association between the number of DMT dispensations and physician claims, negative binomial distributions with GEE were fit as above. Results were reported as rate ratios (RR), with 95% CIs, and calculated for every 1000 DMT dispensations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The number of DMT dispensations was associated with a decreased risk for all-cause (RR=0.994; 95%\u2009CI 0.992 to 0.996) and MS-specific (RR=0.909; 95%\u2009CI 0.880 to 0.938) hospitalisations. The number of DMT dispensations was not associated with the number of all-cause (RR=1.006; 95%\u2009CI 0.990 to 1.022) or MS-specific (RR=0.962; 95%\u2009CI 0.910 to 1.016) physician claims.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Increased DMT use in Saskatchewan was associated with a reduction in hospitalisations, but did not impact the number of physician services used. Additional research on cost-benefit and differing treatment strategies would provide further insight into the true impact of DMTs on healthcare utilisation at a population level.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2019-033599","type":"journal-article","created":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T05:55:18Z","timestamp":1574747718000},"page":"e033599","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Association between disease-modifying therapies for multiple sclerosis and healthcare utilisation on a population level: a retrospective cohort study"],"prefix":"10.1136","volume":"9","author":[{"given":"Lina","family":"Al-Sakran","sequence":"first","affiliation":[{"name":"College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, Saskatchewan, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth Ann","family":"Marrie","sequence":"additional","affiliation":[{"name":"Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Blackburn","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, Saskatchewan, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Knox","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charity","family":"Evans","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, Saskatchewan, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,11,25]]},"reference":[{"key":"2025121600281827000_9.11.e033599.1","doi-asserted-by":"publisher","DOI":"10.2174\/187152712801661266"},{"key":"2025121600281827000_9.11.e033599.2","unstructured":"Multiple Sclerosis Federation . Atlas of MS database 2013. Available: http:\/\/www.atlasofms.org\/index.aspx [Accessed 19 May 2015]."},{"key":"2025121600281827000_9.11.e033599.3","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2014.915802"},{"key":"2025121600281827000_9.11.e033599.4","doi-asserted-by":"crossref","unstructured":"Karampampa K , Gustavsson A , Miltenburger C , et al . Treatment experience, burden, and unmet needs (Tribune) in multiple sclerosis: the costs and utilities of MS patients in Canada. J Popul Ther Clin Pharmacol 2012;19.","DOI":"10.1177\/1352458512441566c"},{"key":"2025121600281827000_9.11.e033599.5","unstructured":"Canadian Institute for Health Information . The Burden of Neurological Diseases,Disorders and Injuries in Canada Ottawa: CIHI; 2007 [Available from. Available: https:\/\/secure.cihi.ca\/free_products\/BND_e.pdf [Accessed 19 Jun 2019]."},{"key":"2025121600281827000_9.11.e033599.6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.24095\/hpcdp.37.2.02","article-title":"Multiple sclerosis in Canada 2011 to 2031: results of a microsimulation modelling study of epidemiological and economic impacts","volume":"37","author":"Amankwah","year":"2017","journal-title":"Health Promot Chronic Dis Prev Can"},{"key":"2025121600281827000_9.11.e033599.7","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-017-0566-3"},{"key":"2025121600281827000_9.11.e033599.8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182270402"},{"key":"2025121600281827000_9.11.e033599.9","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100014244"},{"key":"2025121600281827000_9.11.e033599.10","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/jama.2018.20588","article-title":"Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis","volume":"321","author":"Brown","year":"2019","journal-title":"JAMA"},{"key":"2025121600281827000_9.11.e033599.11","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(76)90061-8"},{"key":"2025121600281827000_9.11.e033599.12","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1185\/03007990902743869","article-title":"Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs","volume":"25","author":"Birnbaum","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"2025121600281827000_9.11.e033599.13","first-page":"735","article-title":"Hospital admissions and MS: temporal trends and patient characteristics","volume":"18","author":"Evans","year":"2012","journal-title":"Am J Manag Care"},{"key":"2025121600281827000_9.11.e033599.14","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000753"},{"key":"2025121600281827000_9.11.e033599.15","doi-asserted-by":"publisher","DOI":"10.1177\/1352458512471877"},{"key":"2025121600281827000_9.11.e033599.16","doi-asserted-by":"publisher","DOI":"10.2165\/11532230-000000000-00000"},{"key":"2025121600281827000_9.11.e033599.17","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1017\/S0317167100005990","article-title":"Health status and health care utilization of multiple sclerosis in Canada","volume":"34","author":"Pohar","year":"2007","journal-title":"Can. j. neurol. sci."},{"key":"2025121600281827000_9.11.e033599.18","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000495"},{"key":"2025121600281827000_9.11.e033599.19","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-317509"},{"key":"2025121600281827000_9.11.e033599.20","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s13311-017-0548-5","article-title":"Therapeutic targets for multiple sclerosis: current treatment goals and future directions","volume":"14","author":"Smith","year":"2017","journal-title":"Neurotherapeutics"},{"key":"2025121600281827000_9.11.e033599.21","doi-asserted-by":"publisher","DOI":"10.1177\/1756285610385608"},{"key":"2025121600281827000_9.11.e033599.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2013.11.002"},{"key":"2025121600281827000_9.11.e033599.23","unstructured":"Non-Insured Health Benefits Program - First Nations and Inuit Health Branch . Annual report 2015-2016. Available: https:\/\/www.canada.ca\/en\/indigenous-services-canada\/services\/first-nations-inuit-health\/reports-publications\/non-insured-health-benefits\/annual-report-2015-2016.html#a2 [Accessed 3 Apr 2019]."},{"key":"2025121600281827000_9.11.e033599.24","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1017\/cjn.2017.301","article-title":"Establishing the incidence and prevalence of multiple sclerosis in Saskatchewan","volume":"45","author":"Al-Sakran","year":"2018","journal-title":"Can. J. Neurol. Sci."},{"key":"2025121600281827000_9.11.e033599.25","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181cf6ec0"},{"key":"2025121600281827000_9.11.e033599.26","unstructured":"Dohoo IR . Methods in epidemiologic research. Prince Edward island. Canada: VER Inc, 2012: 79\u201384."},{"key":"2025121600281827000_9.11.e033599.27","unstructured":"Government of Saskatchewan . Saskatchewan Population Reports 2017 [Available from. Available: http:\/\/www.stats.gov.sk.ca\/pop\/ [Accessed September 26,2017]."},{"key":"2025121600281827000_9.11.e033599.28","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100015961"},{"key":"2025121600281827000_9.11.e033599.29","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-015-7842-0"},{"key":"2025121600281827000_9.11.e033599.30","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514556303"},{"key":"2025121600281827000_9.11.e033599.31","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s40120-018-0123-y","article-title":"Treatment patterns, healthcare resource utilization, and costs among Medicare patients with multiple sclerosis in relation to disease-modifying therapy and corticosteroid treatment","volume":"8","author":"Sanchirico","year":"2019","journal-title":"Neurol Ther"},{"key":"2025121600281827000_9.11.e033599.32","unstructured":"Disease modifying therapy and health care resource utilization in multiple sclerosis. Multiple Sclerosis Journal 2017."},{"key":"2025121600281827000_9.11.e033599.33","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.msard.2015.05.010","article-title":"Health care utilization before and after intensive care unit admission in multiple sclerosis","volume":"4","author":"Marrie","year":"2015","journal-title":"Mult Scler Relat Disord"},{"key":"2025121600281827000_9.11.e033599.34","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1080\/07853890.2018.1461919","article-title":"Adult hospital admissions associated with multiple sclerosis in Finland in 2004\u20132014","volume":"50","author":"Pirttisalo","year":"2018","journal-title":"Ann Med"},{"key":"2025121600281827000_9.11.e033599.35","unstructured":"Canadian Institute for Health Information . Highlights of 2011\u20132012 Emergency Department Visits and Inpatient Hospitalizations 2013 [Available from. Available: https:\/\/secure.cihi.ca\/free_products\/DAD-NACRS_Quick%20Stats_Highlights_2011-2012_EN_web.pdf [Accessed June 19, 2019]."},{"key":"2025121600281827000_9.11.e033599.36","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3233\/NRE-2012-0731","article-title":"Outcomes of inpatient rehabilitation of patients with multiple sclerosis","volume":"30","author":"Gaber","year":"2012","journal-title":"NeuroRehabilitation"},{"key":"2025121600281827000_9.11.e033599.37","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100006004"},{"key":"2025121600281827000_9.11.e033599.38","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.msard.2016.05.006","article-title":"Adherence and persistence to drug therapies for multiple sclerosis: a population-based study","volume":"8","author":"Evans","year":"2016","journal-title":"Mult Scler Relat Disord"},{"key":"2025121600281827000_9.11.e033599.39","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-016-1532-1","article-title":"Quantifying the relationship between increased disability and health care resource utilization, quality of life, work productivity, health care costs in patients with multiple sclerosis in the US","volume":"16","author":"Jones","year":"2016","journal-title":"BMC Health Serv Res"},{"key":"2025121600281827000_9.11.e033599.40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040135"},{"key":"2025121600281827000_9.11.e033599.41","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-015816","article-title":"Population-Level impact of diabetes integrated care on commissioner payments for inpatient care among people with type 2 diabetes in Cambridgeshire: a postintervention cohort follow-up study","volume":"7","author":"Yu","year":"2017","journal-title":"BMJ Open"},{"key":"2025121600281827000_9.11.e033599.42","doi-asserted-by":"publisher","DOI":"10.1016\/S0195-668X(02)00384-6"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2019-033599","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T08:28:26Z","timestamp":1765873706000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2019-033599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":42,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,11,25]]},"published-print":{"date-parts":[[2019,11]]}},"alternative-id":["10.1136\/bmjopen-2019-033599"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2019-033599","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2019,11]]}}}